Nonalcoholic Fatty Liver Disease

Patients with metabolic dysfunction-associated steatohepatitis who weigh more than 100 kg or a BMI more than 35 kg/m² had “slightly better” response with a 100 mg dose of Rezdiffra, according to data presented at EASL Congress.

Adults with type 1 diabetes who play sports have less insulin resistance and are less likely to develop metabolic dysfunction-associated steatotic liver disease, according to study findings.

NEW ORLEANS — In this video exclusive, Jonathan D. Leffert, MD, talks with Scott D. Isaacs, MD, FACP, FACE, and Sangeeta Kashyap, MD, about nomenclature for liver disease and how endocrinologists should approach screening and treatment.

Hepatic adverse events with bimekizumab were low and consistent through 2 years of treatment among patients with moderate to severe psoriasis, according to a study.

Non-alcoholic fatty liver disease is an independent risk factor for osteoarthritis, according to data published in Arthritis Research & Therapy.

DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.

Vibration-controlled transient elastography and serum-based noninvasive tests show a significant discrepancy in detecting liver fibrosis, according to study findings published in Obesity.

Atopic dermatitis in children may be associated with metabolic syndrome and nonalcoholic fatty liver disease, according to a study.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Elizabeth Ward, MS, RDN, and Hillary Wright, MEd, RDN, LDN, about women’s nutrition and exercise needs as they age.

BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.